Film-trigger applicator (FTA) for improved skin penetration of microneedle using punching force of carboxymethyl cellulose film acting as a microneedle applicator

Youseong Kim1, Hye Su Min1, Jiwoo Shin1, Jeehye Nam1, Geonwoo Kang2, Jeeho Sim1, Huisuk Yang2 and Hyungil Jung1,2*

Abstract

Background: Dissolving microneedle (DMN) is a transdermal drug delivery system that creates pore in the skin and directly deliver drug through the pore channel. DMN is considered as one of the promising system alternatives to injection because it is minimally invasive and free from needle-related issues. However, traditional DMN patch system has limitations of incomplete insertion and need of complex external devices. Here, we designed film-trigger applicator (FTA) system that successfully delivered DMN inside the skin layers using fracture energy of carboxymethyl cellulose (CMC) film via micropillars. We highlighted advantages of FTA system in DMN delivery compared with DMN patch, including that the film itself can act as DMN applicator.

Methods: FTA system consists of DMNs fabricated on the CMC film, DMN array holder having holes aligned to DMN array, and micropillars prepared using general purpose polystyrene. We analyzed punching force on the film by micropillars until the film puncture point at different CMC film concentrations and micropillar diameters. We also compared drug delivery efficiency using rhodamine B fluorescence diffusion and skin penetration using optical coherence tomography (OCT) of FTA with those of conventional DMN patch. In vivo experiments were conducted to evaluate DMN delivery efficiency using C57BL/6 mice and insulin as a model drug.

Results: FTA system showed enhanced delivery efficiency compared with that of the existing DMN patch system. We concluded CMC film as a successful DMN applicator as it showed enhanced DMN penetration in OCT and rhodamine B diffusion studies. Further, we applied FTA on shaved mouse dorsal skin and observed successful skin penetration. The FTA group showed higher level of plasma insulin in vivo than that of the DMN patch group.

Conclusions: FTA system consisting of simple polymer film and micropillars showed enhanced DMN delivery than that of the existing DMN patch system. Because FTA works with simple finger force without sticky patch and external devices, FTA is a novel and promising platform to overcome the limitations of conventional microneedle patch delivery system; we suggest FTA as a next generation applicator for microneedle application in the future.

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

*Correspondence: hjung@yonsei.ac.kr
1 Department of Biotechnology, Yonsei University, 50 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea
Full list of author information is available at the end of the article
Keywords: Dissolving microneedle, Carbohydrate polymer film, Insulin, Transdermal drug delivery, Microneedle applicator

Background

Recently, oral and hypodermic administration routes are the most widely recognized for successful drug delivery [1, 2]. Oral drug delivery route is most convenient way for patients; however, it has limitation of first-pass effect [3]. In other words, only limited number of oral drugs can retain their efficacy while passing through the gastrointestinal tract due to hepatic drug metabolism. In contrast, hypodermic route has an advantage that it allows drugs to be directly injected into the body. However, hypodermic injection can cause acute pain to patient and therefore, demands aid of medical expert during administration [4]. Furthermore, injectable routes generate needle waste, which causes other medical hazards such as contaminations, injuries, and infections. Transdermal drug delivery has been developed as an alternative to the existing drug delivery routes in the point that it avoids needle issues and user compliance may be improved by its convenient usability [5].

A dissolving microneedle (DMN), a representative transdermal drug delivery system, has attracted increasing interest as one of the promising types of drug delivery systems. DMN generally consists of drugs and biodegradable and biocompatible polymers appropriate for skin implantation and previous studies suggested carboxymethylcellulose (CMC) and hyaluronic acid (HA) as promising candidates of DMN's structure polymers [6–9]. DMN delivers drugs after penetration and being dissolved by the interstitial fluid under the skin surface [10]. Since DMN delivery is minimally invasive and painless without generating needle waste [11, 12], it can overcome disadvantages of hypodermic injections such as acute pain, hypertrophic scar, bleeding, and other issues and is considered as a next generation drug delivery system. Therefore, DMN is widely used for delivery of various drug candidates, for example, vaccines, insulin, small molecules, and steroids.

Although DMN has potential of a promising drug delivery platform, it has limitation related to its administration method. DMN is generally administered as a sticky patch containing drug and polymer, which needs to be adhered to the skin after penetration until dissolved by the interstitial fluid [13]. Although application of patch by finger force is convenient, DMN patch system has a limitation of incomplete insertion into skin even when applied using external applicator devices. The basal compartment of DMN does not show effective penetration into the skin after patch administration [14, 15]. Moreover, the applied finger force does not evenly distribute on DMN patch so it is hard to make the DMN successfully penetrate skin [16]. If the microneedle is not sufficiently penetrated into the skin, it may fail to deliver a fixed dose of drug after DMN administration because the DMN is fabricated with drug and polymer. To solve this problem, researchers introduced tip loading DMN patch system [17]. Tip loading DMN is a well-designed microneedle system that can overcome the disadvantage of incomplete insertion of the basal compartment of DMN by loading drug only in the tip compartment of DMN. However, since this system has difficulty in utilizing the basal compartment’s volume, it needs an additional drug concentration condensation step or multiple numbers of DMN in an array to satisfy the drug dose. Thus, insertion of DMN need to be improved to achieve effective drug delivery.

To overcome the limitation of insertion of microneedle patch, researchers have developed various applicators to enhance insertion of DMN patches [18–20]. Generally, a patch applicator consists of an even plate to press the patch and external power source to provide a sufficient force to the plate [21]. Because patch applicators are designed to press the back of DMN patch with plate, the researchers utilized either physical force of compressed spring [22–24] or pressing force of machine [25, 26]. Although these patch applicators allow relatively even distribution of force to DMN patch and improved DMN insertion rate than when administration using finger force, inevitable use of external power source makes this system more complex. Also, these complex external devices attenuate the advantages of a simple patch system that requires only finger force. In addition, sticky patch is still required for the DMN to attach to the skin until it is sufficiently dissolved by the interstitial fluid. Collectively, an ideal applicator should work with simple finger force and avoid complex system and sticky patch.

In this study, we introduce novel patchless DMN application system called film-trigger applicator (FTA). In this system, DMNs are fabricated on the surface of CMC polymer film and micropillars are aligned to the bottom of each DMN. In FTA, DMNs are shot to penetrate the skin without using sticky patch and complex external devices. Further, the FTA system uses an accumulated energy of finger force on the carbohydrate polymer film via micropillars, and the film acts like a trigger of a gun at a film puncture point. Here, we used physical property of the film; it breaks at the limit punching force when the
film accumulates sufficient energy by micropillars, FTA operates with finger force and is different from existing applicators that use external energy sources. We analyzed physical properties of the CMC polymer film and performed in vitro skin penetration test using different concentrations of CMC and micropillar diameters to evaluate this novel system. Moreover, we designed in vitro experiments, including optical coherence tomography (OCT) and fluorescent dye diffusion in cadaver skin, for further evaluation. The results of OCT ascertained improved physical penetration and fluorescence data showed superior drug diffusion of the FTA system compared with that of conventional DMN patch application. Furthermore, we used insulin as target drug for in vivo experiments to show efficient drug delivery of the FTA system and observed enhanced insulin delivery by FTA using only finger force without any external force source compared with that of the existing microneedle patch delivery systems.

Methods
Materials
CMC (90 kDa) and human insulin were purchased from Sigma-Aldrich (St. Louis, MO, USA). HA (30 kDa) was purchased from Uscare Pharm (Suwon, Republic of Korea). Sterile microtube (2.0 mL) was purchased from Anxygen Inc. (Union city, CA, USA). Human insulin ELISA kit ((80-INSHU-E01.1) was purchased from ALPCO (Salem, NH, USA). Blood glucose detection kit (ACCU-CHEK) was purchased from Roche (Basel, Switzerland).

Preparation of CMC polymer film, Micropillar and array holder
We selected CMC as the polymer film material because it is biodegradable and biocompatible carbohydrate polymer widely used for microneedle fabrication [27–29]. CMC powder was dissolved in distilled water to prepare solutions of 2% (w/v), 4% (w/v), and 6% (w/v) for fabricating CMC films of square shape on stainless-steel frame. The metal frames were subjected to vacuum plasma treatment to increase polymer attraction on the frame; 300 μL CMC solution of each concentration was poured on the square frame of size 2.5 × 2.5 cm². The solution was dried for 12 h at room temperature (25 °C) to obtain CMC film.

Methods
Material
DMN fabrication and morphology
DMNs were fabricated in candlelit microneedle (CMN) conformation following two steps of fabrication of base layer and head layer [13]. HA aqueous solution (20% w/v) droplets were dispensed on the CMC film and placed in contact with a cover hydrophobic plate. A sandglass shape was obtained by vacuum drying with a constant distance of 300 μm between the two plates. Subsequently, HA aqueous solution (60% w/v) droplets were dispensed on sandglass structures and subjected to centrifugal lithography at 202 g force for 1 min. All DMN solutions
were loaded with 0.1 IU insulin per 25 microneedles [33, 34]. DMNs were fabricated using cold jacket and stored at 4 °C. Morphological conformation of the fabricated microneedles was observed using a bright field microscope (M165 FC; Leica, Wetzlar, Germany) and surface of DMNs was analyzed using scanning electron microscope (SEM, IT-500HR; JEOL, Tokyo, Japan).

High-performance liquid chromatography (HPLC) of fabricated insulin loading DMN
We analyzed insulin amount in DMN using reverse-phase HPLC (Waters 600S, Waters, Milford, MA, USA) with a C18 column (150 mm × 4.6 i. d., Cosmosil 5C18-AR-II, Nacalai Tesque Inc., Kyoto, Japan). We set our mobile phase with solution A (aqueous solution of 0.2 M anhydrous sodium sulfate with phosphoric acid; pH 2.3) and solution B (0.1% v/v, trifluoroacetic acid in acetonitrile). We ran the machine with isocratic phase A:B (3:1). The wavelength for detecting insulin was 214 nm and flow rate was 1.0 mL/min. We serially diluted a sample solution of insulin with PBS (from 0 to 500 μg/mL) to prepare a calibration curve to meet R square value ≥ 0.99.

Pharmacokinetic analysis of DMN delivery system
Pharmacokinetic were calculated from the plasma insulin concentrations versus time. The maximum drug concentration. The area under the drug concentration versus time after administration curve (AUC) was calculated and we finally determined the bioavailability by following equation below.

\[
\% \text{ bioavailability} = \left[ \frac{\text{AUC(DMN)}}{\text{AUC(injection)}} \right] \times \left[ \frac{\text{injection dose}}{\text{DMN dose}} \right] \times 100
\]

Optical coherence tomography
The skin penetration ability of DMN patch and FTA were analyzed by OCT (Kyungpook National University, Daegu, Korea). Shaved pig cadaver skin (approximately 1.0–1.2 mm thickness; Cronex, Hwaseong, Korea) was treated with DMN and its penetration ability was observed by OCT without histological sections.

Skin permeation analysis using rhodamine B as fluorescent model dye
We applied 25 microneedles (5 × 5 arrays) each to pig cadaver skin using DMN patch and FTA. We conducted in vitro skin permeation study by substituting insulin with rhodamine B (Sigma-Aldrich). After 12 h, rhodamine B fluorescence were obtained M165 FC fluorescence microscope (Leica), and fluorescence intensity was calculated using the ImageJ software (National Institutes of Health, Bethesda, MD, USA). We visualized fluorescence diffusion from the bottom view opposite of microneedles penetration site (n = 5/group) [35].

Animals and ethical approval
We followed the ethical guidelines and regulations of the Yonsei Laboratory Animal Research Center (YLARC) for animal experiments. Institutional Animal Care and Use Committee (IACUC, approval number: IACUC-A-202110–1354-02) of the Yonsei University approved all procedures. Female C57BL/6 mice (6-weeks old) were purchased from Orient Bio (Seongnam, Korea) and allowed to adapt for one week. Mice in microneedle administration group were shaved for microneedle insertion. The mice were treated with insulin (0.1 IU) through subcutaneous injection, DMN patch, and FTA (n = 5/group). Mice of all groups were kept under fasting condition for 12 h before the experiments. All mice were housed at room temperature (22–24 °C) with a 12 h light/dark cycle.

Tracing residual DMN after administration of DMN patch and FTA
For tracing dissolution of microneedles in DMN patch, we detached DMN patch from the skin after 5, 10, 15, and 30 min. However, we could not detach microneedles applied by FTA because the microneedles were implanted inside the skin. Thus, we vertically observed the microneedles administered skin by FTA in 5, 10, 15, and 30 min.

Blood glucose monitoring and plasma insulin detection
In animal experiments, we selected 3 × 3 array DMNs to meet 0.1 IU/array as mice application dose. DMNs loading 0.1 IU insulin were administered to the skin via DMN patch and FTA along with positive control (0.1 IU subcutaneous injection of insulin) and negative control (without treatment). Mice of each group were fasted for 12 h before the experiments. After administration of subcutaneous injection, DMN patch, and FTA, we monitored blood glucose (mg/dL) at 0, 1, 2, 4, 8, and 12 h using blood glucose detector (ACCU-CHEK). We simultaneously collected tail vein blood (100 μL) from mice of all groups including negative control at 0, 2, 4, 8, and 12 h. The collected blood samples were centrifuged in 300 × g for 15 min to obtain supernatant fluids. The plasma insulin concentration (µIU/mL) in supernatant
fluid was analyzed by insulin ELISA kit (80-INSHUE01.1). The number of mice in each experiment was five.

Statistical analysis

SPSS (IBM, Armonk, NY, USA) was used for statistical analyses. All data were analyzed by one-way analysis of variance (ANOVA) followed by Scheffe post-hoc test or Student’s t-test. Statistical significance was set at $p < 0.05$ ($^* p < 0.05$, $^{**} p < 0.01$, $^{***} p < 0.001$).

Results

Preparation of carbohydrate polymer film for FTA system and its force analysis

FTA is a patchless system of DMN administration, which enables implantation of DMNs inside the skin using carbohydrate polymer film. As shown in Fig. 1a, the FTA system consists of three parts: micropillars, DMNs fabricated on carbohydrate film, and array holder. When a force is applied vertically to the plain of the film, it is accumulated as energy until the film punctures
In other words, when a force is applied on the film by the micropillars, it changes the distance (length change) of the film until it reaches the puncture resistance. The energy required for film puncture is accumulated until its puncture, and DMNs use this energy to penetrate the skin (Fig. 1b). We utilized the physical properties of the film for DMN penetration; micropillars also play crucial role in applying force on the film until accumulation of sufficient energy.

The FTA system is different from the existing DMN applicators as it operates through applied force on the polymer film (Fig. 1c). The existing DMN applicators control its application force using elastic force of a spring, whereas the FTA system utilizes accumulated force applied on the polymer film through micropillars. The existing DMN patch application system has a limitation of residual DMN patch after detaching from the skin, whereas the FTA system enables DMN insertion without sticky patch and with relatively enhanced drug delivery compared with that of the existing DMN patch.

To explain our FTA concept, fabrication of the film from CMC polymer solution, DMN fabrication on the film, and application steps are illustrated in Fig. 2. We fabricated the CMC polymer films (Fig. 2a) by drying the polymer solution. Next, we fabricated DMNs on the film by centrifugal lithography [36] in CMN conformation (Fig. 2b) [37]. For DMN fabrication, we dispensed HA droplets on the film, which were dried by contacting a hydrophobic plate to obtain sandglass-like shape initially. We then dispensed secondary droplets on the sandglass structures and fabricated DMN by centrifugal force (202 g) using a customized rotor.

The application steps of FTA works are described in Fig. 2c. First, each DMN from the array was aligned on the holes of the FTA array holder (the holes in array holder were designed to match DMNs in array). Next, the micropillars applied force on the film, which was accumulated as energy and punctured the film when it reaches the limit of puncture resistance. At the moment of film puncture, the micropillars pushed DMNs through the holes (diameter = 500 µm) using accumulated energy until the puncture resistance, and DMNs penetrated the skin. The diameter and height of micropillar were 350 µm and 1.5 mm, respectively (Fig. 2d). The usage example of the FTA described in Fig. 2e. The micropillar’s diameter was designed smaller than the bottom diameter of DMN (421 ± 32 µm) (see Additional file 1).

To identify mechanism of FTA application, we analyzed the force values applied on CMC films until film puncture using 2%, 4%, and 6% CMC film. The principal of force analyzer is illustrated in Fig. 3a. We aligned micropillars on the DMN array, and the sensor of the force analyzer was moved toward the micropillars. When the sensor came in contact with the micropillars, it started to push the micropillars, and the force value increased until film puncture. The distance moved by the sensor after the sensor contacts with the micropillar for each film concentration was approximately 0.5 mm, and it is inferred that the area beneath the force-distance graph may be translated as energy accumulated on the film (Fig. 3b) using Eq. (3) presented in Methods section. Finally, the film was punctured and DMNs on the film were shot similar to pulling the trigger of a gun. The force value from the force analyzer plunged after film puncture. The value of punching force at film puncture point was gradually increased according to the concentration of CMC films. The values of punching force were 4.35 ± 0.62 N (2%), 8.02 ± 1.29 N (4%), and 11.05 ± 1.07 N (6%) (Fig. 3b & c). We did not conduct experiment with polymer concentration of CMC film more than 6% because it is known that single finger force of ordinary people is approximately 12 N [38].

Furthermore, we measured punching force at film puncture point for each of 2%, 4%, and 6% CMC film at different micropillars’ diameter of 300 µm, 350 µm, and 400 µm (Fig. 3d) and observed that the force required for film puncture had a correlation between force and micropillars’ diameter as shown in Table 1. We observed that the punching force increased with increase in micropillar’s diameter (Fig. 3e). The film puncture force of 300 µm micropillars for 2%, 4%, and 6% CMC films was 3.10, 6.20, and 7.71 N respectively for 350 µm micropillars, and 5.54, 10.26, and 15.83 N respectively for 400 µm micropillars. To sum up, film punching force showed a tendency to increase with increase in polymer concentration and micropillar diameter.

**Evaluation of DMN penetration of the FTA system using OCT imaging and drug diffusion using rhodamine B model dye**

We used rhodamine B as model dye for visualizing delivery efficiency of the FTA system. Figure 4a shows conformation of rhodamine B-loaded DMN obtained using optical microscope and SEM. Optical microscopic image showed that the DMN array had a homogeneous shape and SEM image revealed that DMNs had smooth and fine surface texture. Figure 4b shows the view-point of administered DMN. Interestingly, DMN penetration into pig cadaver skin was different at different CMC film concentrations of the FTA system, as shown in the side view of DMN administration (Fig. 4c). With 2% CMC film, DMN penetration was unsuccessful with force value of 4.35 ± 0.24 N. Surprisingly, when 4% (8.02 ± 0.30 N) and 6% (11.05 ± 0.42 N) CMC films were used, DMN penetration was successful. In particular, 6% CMC film concentration showed more penetration than that of 4% film.
Fig. 2  

**a** Schematic steps for fabrication of carbohydrate polymer CMC film.  
**b** Schematic steps for fabrication of DMN on CMC film.  
**c** Light microscope and schematic images of FTA application steps (Scale bar, 500 µm).  
**d** Light microscope image of general purpose polystyrene micropillars (Scale bar, 500 µm).  
**e** Example of expected human application site for FTA.
Because OCT shows vertical section of DMN-administered skin [39], we acquired OCT image for observing penetration and insertion of DMN patch and FTA using 6% film that showed the most successful penetration among all experimental groups (Fig. 4d). For comparison, DMN patch was applied using a patch applicator having a round shape plate and designed according to DMN patch size (diameter: 2 cm) to press the back of DMN patch because improved DMN insertion was observed by using a patch applicator compared
with that of bare hand application [40]. DMN patch applicator could apply a force of 3.60 kgf (approximately 35.28 N) to the patch for skin insertion. However, in OCT image of DMN patch, we could observe incomplete insertion of basal compartment of DMN (yellow arrowhead) because of its method of patch administration. On the other hand, FTA enabled insertion of bottom compartment of DMN into the skin.

In addition, we administered rhodamine B fluorescent dye-encapsulated DMN to pig cadaver skin through DMN patch and FTA (Fig. 4e). Higher fluorescent intensity was detected in the bottom view because fluorescence diffuses vertically deeper inside pig cadaver skin. We observed greater fluorescence intensity after 12 h in the FTA group (102.52 ± 7.81) than that in the DMN patch group (70.36 ± 3.83); the intensity was described as relative fluorescent intensity analyzed using the ImageJ software (see Additional file 2).

### Insulin delivery efficiency of FTA system in vivo

We assesses fluorescent model dye delivery efficiency of FTA system in vitro. Further, we selected insulin for evaluation of delivery efficiency of FTA in vivo because insulin delivery can be easily traced by measuring blood glucose level. Furthermore, we compared the rate of insulin delivery from the FTA system and DMN patch by measuring plasma insulin level. We also confirmed DMN penetration by the FTA system into live animal skin through successful insertion of rhodamine B-loaded DMN by FTA as visualized in Fig. 5a. We showed the top

| Micropillar diameter | 300 µm | 350 µm | 400 µm |
|----------------------|--------|--------|--------|
| 2% CMC film          | 3.10 N | 4.32 N | 5.54 N |
| 4% CMC film          | 6.20 N | 7.98 N | 10.26 N|
| 6% CMC film          | 7.71 N | 11.05 N| 15.83 N|

**Table 1** Average film puncture force of 2%, 4%, and 6% CMC film with different micropillars’ diameters

---

**Fig. 4** DMN penetration analysis and rhodamine B model drug diffusion test using FTA system in vitro. **a** Optical microscope and SEM images of DMN arrays fabricated on the film (Scale bar, 1 mm). **b** View-point instruction of DMN application using FTA. **c** DMN application efficiency of FTA system at different concentrations of CMC films (Scale bar, 500 µm). **d** OCT images of DMN patch and FTA system. Dashed line indicates the shape of DMN inserted in the skin. Arrowhead indicates cavity formed after DMN patch application (Scale bar, 500 µm). **e** The bottom view of fluorescence diffusion of rhodamine B-loaded DMN applied to the porcine skin at 12 h after penetration (Scale bar, 1 mm)
and side view of DMNs inserted into shaved mice skin. We could only detect the bottom view of DMNs, demonstrating that our FTA successfully lead DMNs to penetrate the skin barrier.

Further, we assessed dissolution of inserted insulin DMN patches on mice skin (Fig. 5b) by detaching them from mouse dorsal skin after 5, 10, 15, and 30 min because it is widely known that DMN patches needs approximately 30 min to dissolve [41]. DMN patch’s top view was hard to detect because of sticky patch’s opaque material and DMNs implanted by FTA were not able to detach because those are implanted into skin and quickly turns into gel by interstitial fluids. Thus, we observed DMN dissolution over time on mouse dorsal skin using the method described in Fig. 5b. We first applied DMN patches on live mouse dorsal skin using DMN patch applicator and detached the patches for observing after 5, 10, 15, and 30 min. As a result, we observed some remains in insulin DMN patches shown by yellow dashed line. In contrast, in the FTA experimental group, we could observe only the bottom surface’s conformation of insulin-loaded DMNs until 5 min after insertion. Interestingly, the bottom of insulin DMNs swelled due to interstitial fluid absorption in 10 min after insertion.

**Fig. 5 Mouse in vivo experiments of FTA system** (a) Visualization of successful skin insertion using rhodamine B-loaded DMN into mouse skin (Scale bar, 500 µm). (b) Description for the observation concept and dissolution of insulin microneedle leftovers in DMN patch and dissolution of microneedles administered into mouse skin using FTA (Scale bar, 500 µm). (c) Blood glucose level in the control, subcutaneous insulin injection, insulin DMN patch, and insulin DMN FTA groups (n = 5, mean ± S.E.). (d) Plasma insulin level of the control, subcutaneous insulin injection, DMN patch, and FTA groups (n = 5, mean ± S.E.). (e) Plasma insulin concentration in the DMN patch and FTA groups expressed in a bar graph. Statistical significance was set at p < 0.05, **p < 0.01, ***p < 0.001. n.s. indicates non-significant.
Finally, insulin DMNs were completely dissolved and absorbed, and we could detect only pore without DMN remains at 30 min after insertion in the FTA group. The yellow dashed circles (Fig. 5b) indicate insulin DMN leftovers after FTA application on mouse dorsal skin.

In *in vivo* experiment, insulin (0.1 IU) was loaded in all experimental groups (subcutaneous injection, DMN patch, and FTA). The blood glucose levels were measured at 0, 1, 2, 4, 8, and 12 h (Fig. 5c, Additional file 3a). Marked decrease in blood glucose level within 1 h (22.00 ± 1.34 mg/dL) along with fast recovery of blood glucose level between 4 h (22.63 ± 4.63 mg/dL) and 8 h (55.81 ± 4.26 mg/dL) was detected in the insulin injection group. Conversely, the blood glucose level in the FTA group (35.01 ± 6.98 mg/dL) within 1 h was higher than that of the injection group, and it showed slower recovery than that of the insulin injection group between 4 h (29.36 ± 2.02 mg/dL) and 8 h (35.80 ± 4.21 mg/dL). In addition, the FTA group delivered higher amount of insulin than that of the DMN patch group because the FTA group showed higher plasma insulin levels that of the DMN patch group (195.12 ± 29.71 µIU/mL, and 39.97 ± 13.70 µIU/mL, respectively) (Fig. 5d & e).

**Discussion**

**Preparation of CMC polymer film for FTA system and its force analysis**

As we described in the Results section, the film punching force was 4.35 ± 0.62 N (2%), 8.02 ± 1.29 N (4%), and 11.05 ± 1.07 N (6%) with 350 µm micropillar diameter, indicating that the film punching force increases with increase in the film’s polymer concentration with same micropillar diameter because the thickness of the film increases at higher CMC concentration in (see Additional file 4). In addition, we observed that the punching force needed for film puncture is proportional to the diameter of micropillars at same film concentration (Table 1). We have shown that the distance moved by the sensor was approximately 0.5 mm in each group with different film polymer concentration; the area under the force-sensor moving distance graph indicates accumulated energy on the film until film puncture at each polymer concentration. The reason for 2% film being unable to penetrate the porcine skin (Fig. 4c) was that the corresponding FTA could not accumulate sufficient energy to insert DMN into the skin. Contrarily, the FTA system with 4% film showed highly improved DMN insertion but was not completely successful. Surprisingly, FTA with 6% CMC film showed penetration of all DMNs in array into the cadaver skin. These results suggest that a punching force of 11 N of 6% film is desirable to effectively administer DMNs into the skin. Thus, we inferred that film thickness determined by film CMC concentration affected the punching force based on the data (Additional file 4, Table 1) and Eq. (1) described in the Methods section.

We also showed a correlation between force and micropillars’ diameter (area) in Table 1. The force needed for film puncture increased with increase in micropillar’s diameter (Fig. 3e). For example, the film puncture force of 6% CMC film, which was selected for in vivo experiment, with 350 µm micropillar diameter (11.05 N) was higher than that with 300 µm micropillar diameter (7.71 N), and it was higher with 400 µm micropillar diameter (15.83 N) than that with 350 µm micropillar diameter (11.05 N). It might be due to greater force being required to make puncture with micropillars having large diameter and area at the same film concentration. This implied that film puncture force is also controlled for FTA application by adjusting micropillars’ diameter and film concentration.

**Evaluation DMN penetration of the FTA system using OCT imaging and drug diffusion using rhodamine B model dye**

Figure 4d shows OCT image of DMN patch, which reveals incomplete insertion of DMN (yellow arrowhead) because of its method of patch administration. It might be due to the even plate of DMN patch applicator is not suitable for actual uneven indentation on the skin surface generated by sharp DMNs being pressed against the skin, which leaves space between the patch and skin indicated by yellow arrow-heads in Fig. 4d. However, compared with DMN patch application, FTA application allowed insertion of the most part of DMN into the skin and it might penetrate epidermis layer and reach upper dermis considering the height of DMN (750–800 µm). It is expected that micropillars in FTA individually aid insertion of each single DMN and leave less space because micropillars has markedly narrow area in contact with the skin compared with that of DMN patch applicator. In addition, micropillars have advantage of insertion force; for instance, DMN patch applicator could apply a force of 3.6 kgf (approximately 35.28 N), however, it had difficulty in DMN skin insertion compared with that of FTA with 6% CMC film that could apply a force of approximately 11 N. These results are due to difference in the area of contact with the skin. DMN patch applicator had 1π cm² of plate area, which was approximately 33-fold of 0.03π cm² of 25 micropillars’ area. Thus, FTA with narrow area of contact with the skin caused by micropillar may be less likely to meet uneven skin surface causing development of space between the skin and DMNs. Further, according to the Eq. (2) described in the Methods section, extremely smaller cross-sectional area is advantageous for DMN skin penetration because more energy.
per unit area may be transferred with the smaller cross-sectional area under same force value. Thus, we ascertained that FTA successfully inserted DMNs into the skin with proper CMC film concentration.

Additionally, Fig. 4d and e showed that FTA inserted DMNs into deeper skin layers, affecting deeper drug diffusion into the skin. We administered rhodamine B-loaded DMN into pig cadaver skin using DMN patch and FTA. We detected stronger fluorescence intensity of rhodamine B in the bottom view due to diffusion of rhodamine B deeper inside the cadaver skin. Thus, we observed fluorescence in the bottom view of pig cadaver skin, which implied vertical drug diffusion, and it was obtained 12 h after DMN skin penetration because it was needed to confirm the delivery pattern after sufficient diffusion time had elapsed. Moreover, we detected higher fluorescence intensity in the FTA group (102.52 ± 7.81) than that in the DMN patch group (70.36 ± 3.83) (see Additional file 2).

**Insulin delivery efficiency of FTA system in vivo**

We measured blood glucose levels at 0, 1, 2, 4, 8, and 12 h (Fig. 5c, Additional file 3a). The results implied that FTA was able to decrease blood glucose level continuously and slowly until 8 h, in contrast to insulin injection that showed marked decrease in blood glucose level until 2 h and fast recovery of blood glucose level between 4 and 8 h. These results explained that whether delivery routes were affected by the skin barrier or not. In other words, the subcutaneous injection route rapidly delivered drugs inside the body without disturbance of skin barrier, whereas insulin encapsulated in DMN was released at a slower rate because of the hinderance of the skin barrier to diffusion of drug [42].

Interestingly, we observed that FTA showed enhanced insulin DMN delivery efficiency than that of the existing DMN patch system as the FTA group showed lower levels of blood glucose than those of the DMN patch group (29.36 ± 2.02 mg/dL versus 44.08 ± 9.24 mg/dL and 35.80 ± 4.21 mg/dL versus 50.25 ± 13.09 mg/dL in 4 and 8 h, respectively) (Fig. 5c, Additional file 3a). This result matched with higher levels of plasma insulin in the FTA group than those in the DMN patch group (195.12 ± 15.54 µU/mL versus 159.01 ± 13.70 µU/mL [approximately 1.23-fold], 94.55 ± 15.43 µU/mL versus 67.33 ± 3.50 µU/mL [1.41-fold], and 39.97 ± 11.70 µU/mL versus 17.07 ± 1.32 µU/mL [2.35-fold] in 2, 4, and 8 h, respectively) (Fig. 5d & e, Additional file 3b); the difference in insulin level might be due to DMN remains in patch application (Fig. 5b). In further, Fig. 5D and E indicate plasma insulin concentration versus time after dosage of mice and we calculated area under the curve (AUC) values of FTA and DMN patch groups when the injection group’s AUC value was set to 1. The AUC value implies bioavailability of delivered drug through each delivery platform [43]. In surprise, bioavailability of FTA group was 93% which was comparable to bioavailability of injection group (100%) and 1.37-fold higher than that of DMN patch group (68%).

Our FTA system is platform for the DMN delivery, therefore any drugs, which are suitable for loading into the DMN can be candidate for our system. We demonstrated our FTA’s superior delivery efficacy than existing DMN patch with stable DMN formulation [44]. However, it will be needed to conduct skin safety test such as skin irritation and skin sensitive rate because DMN is delivered by transdermal route. In our further study, we believe that we can solve the issues we suggested.

We compared DMN insertion and drug delivery efficiency of FTA with those of the existing DMN patch through in vivo test. In addition, FTA group showed the maximum penetration of DMN inside the skin, even with only finger force (11.05 N) being applied compared with patch applicator’s spring elastic force (35.28 N). To sum up, the FTA system showed enhanced DMN drug delivery efficiency with application of only finger force via micropillars compared with that of the existing DMN patch. Thus, our FTA system is a novel and promising platform that can overcome the problem of insertion of DMN patch inside the skin.

**Conclusions**

In this study, we successfully fabricated an applicator that work based on the novel concept of accumulated energy on polymer film through micropillars without any additional force application device; moreover, its application efficiency has been shown in an animal model using insulin as a model drug. By force analysis of CMC film, we ascertained that the film puncture force could be controlled by adjusting the concentration of polymer solution and diameter of micropillar. Since FTA showed successful and effective delivery of the protein drug insulin in vivo, we expect that FTA system may be finally utilized in delivering DMN-loaded drugs, such as vaccines, biosimilars, proteins, small molecules, steroids, and hormones, which are widely known drug candidates for microneedle application. In conclusion, our FTA system is a novel and promising platform and alternative to conventional DMN patch system with its improved productivity by its superior delivery rate and bioavailability; we suggest FTA as a new generation applicator for microneedle application in the future.

**Abbreviations**

FTA: Film-trigger applicator; DMN: Dissolving microneedle; HA: Hyaluronic acid; CMC: Carboxymethyl cellulose; OCT: Optical coherence tomography; SEM: Scanning electron microscope; S.E.: Standard error; n.s.: Non-significant.
Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s40824-022-00302-5.

Additional file 1. A zoomed image of single micropillar and DMN. DMN bottom diameter is larger than micropillar’s diameter (350 µm). The micropillar, punctured film, and CMN are indicated by arrowheads (Scale bar, 500 µm).

Additional file 2. Fluorescence intensity at the bottom of cadaver skin in the DMN patch and FTA groups. The value was expressed as relative fluorescence intensity of each group using the ImageJ program (n = 5, mean ± S.E.). The average fluorescence intensity of DMN patch was 70.36 ± 3.83 and FTA was 102.52 ± 7.81. Statistical significance was set at p < 0.05, **p < 0.01, ***p < 0.001.

Additional file 3. (a) Blood glucose level expressed in a bar graph. (b) Plasma insulin level expressed in a bar graph. Statistical significance was set at p < 0.05, **p < 0.01, ***p < 0.001. n.s. indicates non-significant.

Additional file 4. Thickness of films prepared using 2%, 4%, and 6% CMC polymer solution (n = 10, mean ± S.E.). The thickness of films was 12.23 ± 1.20 µm, 23.05 ± 1.35 µm, and 33.14 ± 1.30 µm at 2%, 4%, and 6% CMC film concentrations, respectively.

Acknowledgements

Not applicable.

Authors’ contributions

YK and HJ conceptualized FTA and the experiments. YK supervised all steps of experiments. YK, HSM, JS, and JN carried out ex vivo and in vivo experiments. YK fabricated DMN samples. GK, HY, and JS supported the FTA manufacturing. YK analyzed experimental data and wrote the manuscript. YK and HJ edited the manuscript. All authors read and approved the final manuscript.

Authors’ information

Youseong Kim (ph.D.candidate), Hye Su Min (ph.D. student), Jiwoon Shin (ph.D. student), Jeehye Nam (Master student), Geonwoo Kang (ph.D. candidate, Head of research of Juvic Inc.), Jeeho Sim (Master student), Huisuk Yang (ph.D., CEO of Juvic Inc.)

Hyungil Jung (ph.D.Professor, Department of Biotechnology, Yonsei University-Founder and CSO, Juvic Inc.)

Director, Institute of Bio-Medical Health Care Convergence, Yonsei University Department Head, Integrative Biotechnology & Translational Medicine, Yonsei University Chair, Bio & LivingEngineering Majssor, Global Leaders College, Yonsei University Founder and CSO, Juvic Inc.

Funding

This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HV22C0084), by the Development of original technologies for the next generation vaccines for infectious diseases of the National Research Foundation (NRF) funded by the Korean government (MSIT) (grant number: 1711160295), and by the Brain Korea 21 Four (BK21 Four) program.

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Declarations

Ethics approval and consent to participate

All animal experiments were followed by the ethical guidelines at the Yonsei Laboratory Animal Research Center (YLARC). Institutional Animal Care and Use Committee (IACUC, approval number: IACUC-A-202110–1354-02) of the Yonsei University approved all procedure. All participants were aware of and provided consent to the guidelines of the committee.

Consent for publication

Not applicable.

Competing interests

YK and HJ are inventor of FTA applicator’s patent. Yonsei University have the patent right. This potential conflict of interest has been disclosed and is managed by Yonsei University.

Author details

1 Department of Biotechnology, Yonsei University, 50 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea. 2 Juvic Inc, 208Ho, 272, Digital-ro, Guro-gu, Seoul 08389, Republic of Korea.

Received: 9 August 2022 Accepted: 22 September 2022

Published online: 05 October 2022

References

1. Gupta H, Bhandari D, Sharma A. Recent trends in oral drug delivery: a review. Recent Pat Drug Deliv Formul. 2009;3(2):162–73.

2. Prausnitz MR, Goodson JL, Rota PA, et al. A microneedle patch for measles and rubella vaccination: a game changer for achieving elimination. Curr Opin Virol. 2020;41:68–76.

3. Jung JH, Jin SG. Microneedle for transdermal drug delivery: current trends and fabrication. J Pharm Investig. 2021;51(5):503–17.

4. Yang H, Kang G, Jang M, et al. Development of lidocaine-loaded dissolving microneedle for rapid and efficient local anesthesia. Pharmaceutics. 2020;12(11):1067.

5. Kim YC, Park JH, Prausnitz MR. Microneedles for drug and vaccine delivery. Adv Drug Deliv Rev. 2012;64(14):1547–68.

6. Jeong B, Bae YH, Lee DS, et al. Biodegradable block copolymers as injectable drug-delivery systems. Nature. 1997;388(6645):860–82.

7. Saha I, Rai VK. Hyaluronic acid based microneedle array: recent applications in drug delivery and cosmetology. Carbonyl Polym. 2021;267:118168.

8. Zare MR, Khorram M, Barzegar S, et al. Dissolvable carboxymethyl cellulose/polyvinylpyrrolidone microneedle arrays for transdermal delivery of Amphotericin B to treat cutaneous leishmaniasis. Int J Biol Macromol. 2021;182:1310–21.

9. An S, Choi S, Min S, et al. Hyaluronic acid-based biomimetic hydrogels for tissue engineering and medical applications. Biotechnol Boprocess Eng. 2021;26(4):503–16.

10. Wang Z, Luan J, Seth A, et al. Microneedle patch for the ultrasonic quantification of protein biomarkers in interstitial fluid. Nat Biomed Eng. 2021;5(1):64–76.

11. Gowers SA, Freeman DM, Rawson TM, et al. Development of a minimally invasive microneedle-based sensor for continuous monitoring of β-lactam antibiotic concentrations in vivo. ACS Sens. 2019(4):1072–80.

12. Abramson A, Caffarel-Salvador E, Soares V, et al. A luminal unfolding microneedle injector for oral delivery of macromolecules. Nat Med. 2019;25(10):1512–8.

13. Fakhraei LS, Kim Y, Kang G, et al. Tissue interlocking dissolving microneedles for accurate and efficient transdermal delivery of biomolecules. Sci Rep. 2019;9(1):1–9.

14. Yang Y, Chu H, Zhang Y, et al. Rapidly separable bubble microneedle patch for effective local anesthesia. Nano Res. 2022;15(9):8336–44.

15. Makvandi P, Kirkby M, Hutton AR, et al. Engineering microneedle patches for improved penetration: analysis, skin models and factors affecting needle insertion. Nano-Micro Letters. 2021;13(1):1–41.

16. Fakhraei LS, Seo SH, Kim S, Dangol M, et al. Transcutaneous implantation of valproic acid-encapsulated dissolving microneedles induces hair regrowth. Biomaterials. 2018;167:69–79.

17. Li S, Xia D, Prausnitz MR. Efficient Drug Delivery into Skin Using a Bifacial Dissolvable Microneedle Patch with Water-Insoluble Baking. Adv Func Mater. 2021;31(44):2103359.

18. Kim J, Park S, Nam G, et al. Bionic inspired microneedle insertion for deep and precise skin penetration with low force: Why the application of
mechanophysical stimuli should be considered. J Mech Behav Biomed Mater. 2018;78:480–90.
19. Wang C, Jiang X, Zeng Y, et al. Rapidly separable microneedle patches for controlled release of therapeutics for long-acting therapies. Med Drug Discov. 2021;100118.
20. Jung CR, Fakhraei LS, Kim Y, et al. Rapidly separable micropillar integrated dissolving microneedles. Pharmaceutics. 2020;12(6):581.
21. Ray S, Wirth DM, Ortega-Rivera OA, et al. Dissolving microneedle delivery of a prophylactic HPV vaccine. Biomacromol. 2022;23(3):903–12.
22. Ziesmer J, Tajaifa P, Hempel NJ, et al. Vancomycin-Loaded Microneedle Arrays against Methicillin-Resistant Staphylococcus Aureus Skin Infections. Adv Mater Technol. 2021;6(7):2001307.
23. Laozo E, De Crescenzo G, Nieto-Arreguillo A, et al. Superswelling microneedle arrays for dermal interstitial fluid (prote)omics. Adv Func Mater. 2021;31(46):2106061.
24. Coffey JW, van der Burg NM, Ranakanomol T, et al. An Ultrahigh-Density Microneedle Array for Skin Vaccination: Inducing Epidermal Cell Death by Increasing Microneedle Density Enhances Total IgG and IgG1 Immune Responses. Adv NanoBiomed Res. 2022;2100151.
25. Sakamoto M, Hasegawa Y, Shikida M. Development of spear-shaped microneedle and applicator for tip insertion into artificial skin. Microsyst Technol. 2021;27(10):3907–16.
26. Leone M, Van Oorschot BH, Nejadnik MR, et al. Universal applicator for digitally-controlled pressing force and impact velocity insertion of microneedles into skin. Pharmaceuticals. 2018;10(4):211.
27. Benchabane A, Bekkour K. Rheological properties of carboxymethyl cellulose (CMC) solutions. Colloid Polym Sci. 2008;286(10):1173–80.
28. Rahman M, Hasan M, Nitar AS, et al. Recent developments of carboxymethyl cellulose. Polymers. 2021;13(8):1345.
29. Loizidou EZ, Williams NA, Barrow DA, et al. Structural characterisation and transdermal delivery studies on sugar microneedles: Experimental and finite element modelling analyses. Eur J Pharm Biopharm. 2015;89:224–31.
30. Goyal P, Srivastava G, Singh R, et al. Review on pneumatic punching machine and modification in punch tool to reduce punching force requirement. Int J Eng Technol Sci Res (IJETSIR). 2015;2(2).
31. Hajikarimi P, Nejad FM. Applications of viscoelasticity: Bituminous materials characterization and modeling. Elsevier. 2021.
32. Ding Y, Yu K. All-strength-grade polyethylene engineered cementitious composite (PE-ECC): Mechanical performance, energy parameters and its performance-based design method. In Advances in Engineered Cementitious Composites. Woodhead Publishing. 2022. p. 39–76.
33. Lau S, Fei J, Liu H, et al. Multilayered pyramidal dissolving microneedle patches with flexible pedestals for improving effective drug delivery. J Control Release. 2017;265:113–9.
34. Chen BZ, He MC, Zhang XP, et al. A novel method for fabrication of coated microneedles with homogeneous and controllable drug dosage for transdermal drug delivery. Drug Deliv Transl Res. 2022;1–10.
35. Kim S, Eum J, Yang H, et al. Transdermal finasteride delivery via powder-carrying microneedles with a diffusion enhancer to treat androgenetic alopecia. J Control Release. 2019;316:1–11.
36. Yang H, Kim S, Kang G, et al. Centrifugal lithography: self-shaping of polymer microstructures encapsulating biopharmaceuticals by centrifuging polymer drops. Adv Healthcare Mater. 2017;6(19):1700326.
37. Ohn J, Jang M, Kang BM, Yang H, et al. Dissolving candlelet microneedle for chronic inflammatory skin diseases. Adv Sci. 2021;8(14):2004873.
38. Li K, Nataraj R, Marquardt TL, et al. Directional coordination of thumb and finger forces during precision pinch. PLoS One. 2013;8(1):e79400.
39. Donnelly RF, Garland MJ, Morrow DI, et al. Optical coherence tomography is a valuable tool in the study of the effects of microneedle geometry on skin penetration characteristics and in-skin dissolution. J Control Release. 2010;147(3):333–41.
40. RR Singh T, J Dunne N, Cunningham E, et al. Review of patents on microneedle applicators. Recent Pat Drug Deliv Formul. 2011;5(1):11–23.
41. Lee WJ, Han MR, Kim JS, et al. A tearable dissolving microneedle system for shortening application time. Expert Opin Drug Deliv. 2019;16(3):199–206.
42. Jeppis OG, Danick V, Anissimov YG, et al. Modeling the human skin barrier—Towards a better understanding of dermal absorption. Adv Drug Deliv Rev. 2013;65(2):152–68.
43. Scheff JD, Almon RR, Dubois DC, et al. Assessment of pharmacologic area under the curve when baselines are variable. Pharm Res. 2011;28(5):1081–9.
44. Kim S, Yang H, Eum J, et al. Implantable powder-carrying microneedles for transdermal delivery of high-dose insulin with enhanced activity. Biomaterials. 2020;232:119733.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.